专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20030092145A1 Viral vaccine composition, process, and methods of use 审中-公开
标题翻译：病毒疫苗的组成，过程和使用方法
公开(公告)号：US20030092145A1
公开(公告)日：2003-05-15
申请号：US09935344
申请日：2001-08-23
发明人： Vic Jira , Vichai Jirathitikal
IPC分类号： C12N007/04 , A61K039/165 , A61K039/155 , C12N013/00 , A61K039/145 , A61K039/17 , A61K039/125 , A61K039/193 , A61K039/245 , A61K039/27 , A61K039/23 , A61K009/20
CPC分类号： A61K39/015 , A61K39/0005 , A61K39/0006 , A61K39/001 , A61K39/04 , A61K2039/51 , A61K2039/5252 , A61K2039/541 , A61K2039/542 , A61K2039/552 , C12N2710/14034 , C12N2740/16034 , C12N2760/16134
摘要： A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.
摘要翻译：描述了用于治疗或预防病毒感染的组合物，以及生产组合物的组合物和方法的方法。该组合物包含病毒感染的细胞或组织，或已经被还原和/或变性的恶性或免疫异常的细胞或组织。将优选的组合物施用于患有或约有感染的动物的粘膜表面。该组合物作为预防或治疗性疫苗施用。

2. 发明申请

US20020182228A1 Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins 有权
标题翻译：用于产生包含重组RSV基因组或抗原单核细胞和N，P，L和M2蛋白质的自复制感染性RSV颗粒的方法
公开(公告)号：US20020182228A1
公开(公告)日：2002-12-05
申请号：US09847173
申请日：2001-05-03
发明人： Peter L. Collins
IPC分类号： A61K039/155 , C07H021/04 , C12N007/00 , C12P019/34 , A61K039/395 , C12N007/01 , C12N007/08 , C12N005/00 , A61K039/12 , C12N007/06 , C12N005/02 , C12N007/04 , C12N007/02
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/525 , C12N7/00 , C12N15/86 , C12N2760/18521 , C12N2760/18522 , C12N2760/18543
摘要： Isolated polynucleotide molecules provide RSV genome and antigenomes, including that of human, bovine or murine RSV or RSV-like viruses, and chimera thereof. The recombinant genome or antigenome can be expressed with a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large (L) polymerase protein, and an RNA polymerase elongation factor to produce isolated infectious RSV particles. The recombinant RSV genome and antigenome can be modified to produce desired phenotypic changes, such as attenuated viruses for vaccine use.
摘要翻译：分离的多核苷酸分子提供RSV基因组和抗原单体，包括人，牛或鼠RSV或RSV样病毒及其嵌合体。重组基因组或反向原核基因组可以用核衣壳蛋白（N）蛋白，核衣壳磷蛋白（P），大（L）聚合酶蛋白和RNA聚合酶延伸因子表达，以产生分离的感染性RSV颗粒。可以修饰重组RSV基因组和反义基因组以产生所需的表型变化，例如用于疫苗使用的减毒病毒。

3. 发明申请

US20020034734A1 Vaccine composition for preventing or treating hepatitis C 失效
标题翻译：用于预防或治疗丙型肝炎的疫苗组合物
公开(公告)号：US20020034734A1
公开(公告)日：2002-03-21
申请号：US09916359
申请日：2001-07-26
申请人： Pasteur Merieux Serums & Vaccins
发明人： Veronique Barban
IPC分类号： C07H021/04 , C12P021/06 , C12N001/20 , C12N015/00 , C12N015/09 , C12N015/63 , C12N015/70 , C12N015/74 , C12N005/00 , C12N005/02 , C07K001/00 , C07K014/00 , C07K017/00 , C12Q001/70 , C12P019/34 , C12N013/00 , A61K039/00 , A61K039/12 , A61K039/29 , C12N007/04 , C07K002/00 , C07K004/00 , C07K005/00 , C07K007/00 , C07K016/00 , A61K038/00 , A01N025/00
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/29 , A61K2039/51 , C12N2770/24222 , C12N2770/24234 , Y10S514/934 , Y10S530/826
摘要： The invention concerns a pharmaceutical composition for treating or preventing C hepatitis (HCV), induced infections, which in a preferred embodiment, comprises a main active principle, (i) a fusion polypeptide, including the HCV capsid polypeptide (C191) and polypeptide coat (E1) and in which at least one cleavage site 173/174 and 191/192 has been made inoperative by mutation; (ii) an equimolar mixture of the C191 polypeptide of which the cleavage site 173/174 has been made inoperative and of the E1 polypeptide (mixture equivalent to the fusion polypeptide); or (iii) a DNA molecule coding for this fusion polypeptide. Products (i) to (iii) are characterized in that the C191 element is incapable of regulating the functioning of the genes, in particular of causing them to interact. Such a composition can also include any form equivalent to the products described above.
摘要翻译：本发明涉及用于治疗或预防C型肝炎（HCV）诱导的感染的药物组合物，其在一个优选实施方案中包含主要活性成分，（i）融合多肽，包括HCV衣壳多肽（C191）和多肽外壳（ E1），其中通过突变使至少一个切割位点173/174和191/192不能起作用; （ii）切割位点173/174已经不起作用的C191多肽与E1多肽（与融合多肽相当的混合物）的等摩尔混合物; 或（iii）编码该融合多肽的DNA分子。产品（i）至（iii）的特征在于C191元件不能调节基因的功能，特别是使它们相互作用。这种组合物还可以包括与上述产品相当的任何形式。

4. 发明申请

US20030096259A1 In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs), homogeneous VLP and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents 审中-公开
标题翻译：用于拆分/重新组装乳头瘤病毒病毒样颗粒（VLP）的体外方法，通过所述方法产生的均匀VLP和辣椒素组合物; 其用途是改善纯化和递送活性剂
公开(公告)号：US20030096259A1
公开(公告)日：2003-05-22
申请号：US10138739
申请日：2002-05-06
申请人： Medlmmune, Inc.
发明人： Michael P. McCarthy , JoAnn A. Suzich
IPC分类号： C12Q001/70 , C12Q001/68 , C12N007/00 , C12N007/01 , C12N007/04 , C12N007/02
CPC分类号： C12N7/00 , A61K47/646 , A61K2039/5258 , C07K14/005 , C12N2710/20022 , C12N2710/20023
摘要： A method of disassembly/reassembly of papillomavirus VLPs is provided. The resultant VLPs have enhanced homogeneity, present conformational, neutralizing PV epitopes, and therefore are useful prophylactic and diagnostic agents. Further, these VLPs can be used to encapsulate desired moieties, e.g., therapeutic or diagnostic agents, or nullmarkernull DNAs, and the resultant VLPs used as in vivo delivery vehicles or as pseudovirions for evaluating vaccine efficacy.
摘要翻译：提供了一种拆卸/重新组装乳头瘤病毒VLP的方法。所产生的VLP具有增强的均一性，呈现构象，中和的PV表位，因此是有用的预防和诊断剂。此外，这些VLP可用于包封所需部分，例如治疗或诊断试剂或“标记”DNA，以及用作体内递送载体的所得VLP或用作评估疫苗功效的假病毒。

5. 发明申请

US20020182107A1 Rapid sterilization and vaccine preparation 有权
标题翻译：快速灭菌和疫苗制备
公开(公告)号：US20020182107A1
公开(公告)日：2002-12-05
申请号：US09924266
申请日：2001-08-07
发明人： James A. Laugharn JR. , David W. Bradley , Robert A. Hess
IPC分类号： A61L002/02 , C12N007/04
CPC分类号： A61L2/02 , A23L3/0155 , A61L2/0011
摘要： The invention is based on the discovery that biological and non-biological materials can be sterilized, decontaminated, or disinfected by repeatedly cycling between relatively high and low pressures. Pressure cycling can be carried out at low, ambient, or elevated temperatures (e.g., from about null40null C. to about 95null C., or intermediate ranges). New methods based on this discovery can have applications in, for example, the preparation of vaccines, the sterilization of blood plasma or serum, plant, animal, and human tissue, sputum, urine, feces, water, and ascites, the decontamination of military devices, food and beverage production, and the disinfection of medical equipment. The new methods can also be incorporated into production processes or research procedures.
摘要翻译：本发明基于以下发现：生物和非生物材料可以通过在相对高和低的压力之间重复循环进行灭菌，去污或消毒。压力循环可以在低，环境或升高的温度（例如，约-40℃至约95℃或中等范围）下进行。基于该发现的新方法可以应用于例如疫苗的制备，血浆或血清，植物，动物和人体组织，痰液，尿液，粪便，水和腹水的灭菌，军事的去污设备，食品和饮料生产以及医疗设备的消毒。新的方法也可以纳入生产过程或研究程序。

6. 发明申请

US20020051966A1 Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease 失效
标题翻译：通过腺病毒蛋白酶的异位表达阳性选择腺病毒重组体来有效地产生基于腺病毒的文库
公开(公告)号：US20020051966A1
公开(公告)日：2002-05-02
申请号：US09843949
申请日：2001-04-30
发明人： Bernard Massie , Seyyed Mehdy Elahi , Wahiba Qualikene
IPC分类号： C12N007/00 , C12Q001/70 , G01N033/53 , C12N015/861 , C12N007/04 , C12N015/09 , C12N015/70 , C07H021/02 , C07H021/04 , C12N015/74
CPC分类号： C12N7/00 , A61K39/00 , A61K48/00 , C12N15/86 , C12N2710/10343 , C12N2710/10352 , C12N2810/50 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： Disclosed is a new system for generating recombinant adenovirus vectors and adenovirus-based expression libraries, by positive selection of recombinants deleted for the endogenous protease gene, which gene is expressibly cloned into another region of the adenoviral genome. In a preferred embodiment, the invention allows positive selection of E1-deleted, protease-deleted recombinant adenovirus vectors comprising an exogenous gene or an expressible piece of exogenous DNA, by providing an expression cassette comprising the protease gene and the exogenous DNA inserted in place of E1 region in a shuttle vector. In vivo recombination of the shuttle vector with a protease-deleted adenoviral genome in suitable non-complementing cells generates viable recombinants only when rescuing the protease cloned in E1 region. Non-recombinant viral genomes are not able to grow due to the deletion of the protease gene, ensuring that only recombinant viral plaques are generated. This positive selection can be used for the generation of a large number of high purity recombinant adenovirus vectors and allows generation of adenovirus-based libraries with diversity exceeding 106 clones.
摘要翻译：公开了一种用于产生重组腺病毒载体和基于腺病毒的表达文库的新系统，通过阳性选择为内源性蛋白酶基因缺失的重组体，该基因可表达克隆到腺病毒基因组的另一区域。在一个优选的实施方案中，本发明允许通过提供包含蛋白酶基因的表达盒和插入的外源DNA来代替包含外源基因或可表达外源DNA片段的E1缺失的，蛋白酶缺失的重组腺病毒载体，代替 E1区域在穿梭载体中。穿梭载体与合适的非补体细胞中的蛋白酶缺失型腺病毒基因组的体内重组仅在拯救克隆在E1区域中的蛋白酶时产生可行的重组体。非重组病毒基因组由于蛋白酶基因的缺失而不能生长，确保仅产生重组病毒噬菌斑。这种阳性选择可用于产生大量高纯度重组腺病毒载体，并且允许产生具有超过106个克隆的多样性的基于腺病毒的文库。

7. 发明申请

US20020037575A1 Recombinant virus vectors 审中-公开
标题翻译：重组病毒载体
公开(公告)号：US20020037575A1
公开(公告)日：2002-03-28
申请号：US09833206
申请日：2001-04-10
发明人： Peter G. Speck
IPC分类号： C12N015/869 , C12N007/01 , A61K048/00 , A01N063/00 , A61K039/12 , A61K039/245 , A61K039/255 , A61K039/265 , A61K039/27 , C12N007/00 , C12N007/04 , C12N015/86
CPC分类号： C12N15/86 , C12N2710/16643
摘要： A mutant herpesvirus that can be used as a recombinant virus vector comprises (a) a mutation such that the mutant virus has a reduced ability in comparison with a parent type to cause lysis of an infected cell, and (b) an inactivating mutation in a gene essential for the production of infectious virus. An example is a HSV1 mutant lacking the essential glycoprotein gH gene and having a mutation impairing the function of gene product VP16. A heterologous gene can be carried at the site of the inactivated essential gene, e.g. a gene suitable for administering gene therapy. The vector has an increased margin of safety over known herpesvirus vectors in respect of incidence of cytopathic effects and/or risk of reversion.
摘要翻译：可用作重组病毒载体的突变疱疹病毒包含（a）突变病毒与母体类型相比具有降低的能力以引起感染细胞裂解的突变，和（b）在对感染性病毒生产至关重要的基因。一个例子是缺乏必需糖蛋白gH基因并具有损害基因产物VP16功能的突变的HSV1突变体。异源基因可以在灭活的必需基因的位点携带，例如一种适合基因治疗的基因。载体与已知疱疹病毒载体相比，在致病性病变发生率和/或逆转风险方面具有更高的安全性。

8. 发明申请

US20040131497A1 PROCESS FOR STERILIZATION OF BIOLOGICAL COMPOSITIONS CONTAING PROTEIN 审中-公开
标题翻译：蛋白质生物组合物灭菌方法
公开(公告)号：US20040131497A1
公开(公告)日：2004-07-08
申请号：US10663803
申请日：2003-09-17
发明人： Thomas Lengsfeld , Wolfram Schaefer , Thomas Nowak , Michel Grandgeorge
IPC分类号： A61L002/08 , A61L002/10 , C12N007/04
CPC分类号： A61L2/0041 , A61K47/10 , A61L2/0011 , A61L2/0035 , A61L2/0047 , A61L2/0052 , A61L2/0058 , A61L2/0088 , A61L2/10
摘要： The present invention relates to a method for inactivating microorganisms especially viruses in protein containing biological compositions, especially blood, placental, serum and plasma components or derivatives solutions of human or animal origin or compositions containing proteins obtained by the extraction of vegetal or animal tissues or obtained by biotechnological techniques, i.e. by culture of natural or recombinant cells of bacterial, yeast, plant or human or animal origin thereby retaining the integrity of the desired protein at a degree suitable for its purpose. By extension the method applies to the inactivation of bacterial or viral preparations, when proteic components or proteic antigens are present, which are intended for use in inactivated or non-living vaccines.
摘要翻译：本发明涉及一种使含有蛋白质的生物组合物，特别是血液，胎盘，血清和血浆成分或人源或动物来源的血浆成分或衍生物溶液灭活微生物尤其是病毒的方法，所述组合物含有通过提取植物或动物组织或获得的蛋白质通过生物技术技术，即通过培养细菌，酵母，植物或人或动物来源的天然或重组细胞，从而在适合其目的的程度上保持所需蛋白质的完整性。延伸该方法适用于当存在用于灭活或非活疫苗的蛋白质组分或蛋白质抗原时细菌或病毒制剂的灭活。

9. 发明申请

US20030049830A1 Herpes virus complementing cell line 有权
标题翻译：疱疹病毒补充细胞系
公开(公告)号：US20030049830A1
公开(公告)日：2003-03-13
申请号：US10257229
申请日：2002-10-10
发明人： Karen Metcalfe
IPC分类号： C07H021/04 , C12N007/01 , C12N007/02 , C12N015/09 , C12N015/70 , C12N007/00 , C12N007/04 , C12N015/00 , C12N015/63 , C12N015/74
CPC分类号： C12N7/00 , A61K39/12 , A61K39/245 , A61K2039/5254 , C07K14/005 , C12N2710/16622 , C12N2710/16634 , C12N2710/16652 , C12N2710/16661
摘要： The present invention is directed to a cell line capable of supporting replication of a growth-defective Herpes Simplex Virus strain; specifically a replication-defective HSV-2 double mutant. Particularly disclosed is a cell line that expresses the ICP8 protein and the UL5 protein of Herpes Simplex Virus. This cell line is useful to propagate a replication-defective HSV-2 vaccine strain that contains mutations and/or deletions in the ICP8 and UL5 genes.
摘要翻译：本发明涉及能够支持生长缺陷型单纯疱疹病毒株复制的细胞系; 具体是复制缺陷型HSV-2双突变体。特别公开的是表达单克隆病毒的ICP8蛋白和UL5蛋白的细胞系。该细胞系可用于繁殖在ICP8和UL5基因中含有突变和/或缺失的复制缺陷型HSV-2疫苗株。

10. 发明申请

US20020164356A1 Attenuated recombinant rabies virus mutants and live vaccines thereof 失效
标题翻译：减毒重组狂犬病毒突变体及其活疫苗
公开(公告)号：US20020164356A1
公开(公告)日：2002-11-07
申请号：US10128628
申请日：2002-04-23
发明人： Teshome Mebatsion
IPC分类号： A61K048/00 , A01N063/00 , A61K039/12 , C12N007/04
CPC分类号： C12N7/00 , A61K39/12 , A61K39/205 , A61K2039/525 , A61K2039/5254 , A61K2039/542 , C07K14/005 , C12N2760/20122 , C12N2760/20134 , C12N2760/20161
摘要： The present invention describes recombinant RV mutants comprising a combined mutation in two different parts of the viral genome, involving the P and the G genes. The mutations in the P gene preferably encompass residues 139 to 170, more preferably residues 139 to 149, most preferably residues 143-149. The mutation can be a substitution or deletion of one or more amino acids in the above region, as well as combinations of deletion and substitution. Preferred mutants according to the invention may be obtained by deleting residues 143 to 149 or 139 to 149 of the phosphoprotein (P) of rabies virus and simultaneously replacing the Arg at position 333 of the glycoprotein into another residue, preferably Asp instead of Arg. Surprisingly, when these mutations were introduced into rabies viruses lacking Arg at position 333 of their G protein, a dramatic reduction in pathogenicity for suckling mice was observed. This unexpected finding has a profound advantage in developing more safe live attenuated rabies vaccines. The mutation in the G gene may comprise a mutation of the Arg333 codon into a codon that differs by one, two or three nucleotides from said Arg333 codon. Preferably the mutants are mutants of a RV strain in which all three nucleotides of the Arg333 codon are substituted.
摘要翻译：本发明描述了重组RV突变体，其包含病毒基因组的两个不同部分中的组合突变，涉及P和G基因。 P基因中的突变优选包括残基139至170，更优选残基139至149，最优选残基143-149。突变可以是上述区域中一个或多个氨基酸的取代或缺失，以及缺失和取代的组合。根据本发明的优选突变体可以通过删除狂犬病病毒的磷蛋白（P）的143至149或139至149位，同时将糖蛋白333位的Arg同时替换为另一残基，优选Asp而不是Arg来获得。令人吃惊的是，当这些突变引入到其G蛋白333位缺乏Arg的狂犬病病毒时，观察到乳鼠的致病性显着降低。这种意想不到的发现在开发更安全的减毒狂犬病疫苗方面具有深远的优势。 G基因中的突变可以包括Arg333密码子的突变成从所述Arg333密码子不同一个，两个或三个核苷酸的密码子。优选地，突变体是其中Arg333密码子的所有三个核苷酸都被取代的RV菌株的突变体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式